Navigation Links
SRI International Completes Biosciences Facility Expansion in Shenandoah Valley, Virginia
Date:10/24/2013

MENLO PARK, Calif., Oct. 24, 2013 /PRNewswire/ -- SRI International has completed the final stage of expansion of its 40,000-square foot research and development (R&D) facility in Harrisonburg, Virginia. SRI funded the $2.8 million build-out to further advance its bioscience research capabilities at SRI's Shenandoah Valley (SRI SV) Center for Advanced Drug Research. SRI has also renewed its five-year lease in the Innovation Village at Rockingham, reaffirming its commitment to the region.

SRI's new biomedical facilities include more than 2,500-square feet of laboratory and storage areas for preclinical research, drug discovery, and drug development programs to support growing client and partner needs. R&D at SRI Shenandoah Valley focuses on basic research, including emerging infectious diseases, metabolic diseases, and proteomics; therapeutic discovery and development of drugs, vaccines and biologics; and personalized medicine, such as companion diagnostics and biomarkers.

As part of SRI's growth, renowned experts have joined the SRI Biosciences team. New hires at SRI Shenandoah Valley include:

  • Thomas Voss, Ph.D., Director of Virology, Center for Immunology and Infectious Diseases: Voss' research interests include cell-virus interactions and their role in acute viral infections, as well as therapeutic drug and vaccine development. At SRI, he is continuing his research on new models for developing treatments for influenza and other infectious diseases. He joined SRI from the faculty of Tulane School of Medicine's Department of Microbiology and Immunology. Earlier, he worked in various roles at Southern Research Institute, ultimately as vice president of the Homeland Security and Emerging Infectious Disease Division.
  • Tianyi "Tony" Wang, Ph.D., Senior Scientist, Virology, Center for Immunology and Infectious Diseases: Wang studies the entry mechanism of Hepatitis C virus (HCV) and natural immunity against viruses. His current research includes characterizing the role of the occludin protein in HCV entry and how HCV infection alters the physiology of tight junctions, the areas between cells where membranes join together. Prior to joining SRI, Wang was a faculty member in the University of Pittsburgh's Department of Infectious Diseases and Microbiology.
  • Lynn Chellarajan, Laboratory Supervisor: Chellarajan is the operational manager of SRI's new SRI SV preclinical laboratories and oversees the daily operation of a broad range of toxicology and pharmacology studies conducted to advance promising therapeutics from the discovery stage towards human clinical trials. Prior to joining SRI, she spent more than a decade working in the pharmaceutical industry at PharmaMar USA, Millennium, and Eisai. Chellarajan is actively recruiting additional staff to support SRI's expanding preclinical activities.

"In 2007, a small number of SRI colleagues and I first began working in a laboratory on the campus of James Madison University, which marked the founding of our Center for Advanced Drug Research in Shenandoah Valley. Since then, due in large part to the support of the Commonwealth of Virginia and other regional partners, we have grown and established a state-of-the-art facility tackling the challenges of drug discovery and development for critical and emerging diseases," said Krishna Kodukula, Ph.D., executive director, strategic development and site head of SRI Shenandoah Valley. "Tom Voss, Tony Wang, and Lynn Chellarajan, the most recent staff members to join our team from around the world, are valuable assets in SRI's expanded research capabilities."

SRI's successful growth in Shenandoah Valley has also been demonstrated through regional innovation programs and spin-off companies that have resulted from SRI research and development. Regional and local start-ups include Redcoat Solutions, Inc. and RioGin. Redcoat will soon launch bed bug detection products into commercial and consumer markets. The products will allow users to quickly determine when a room is infested with bed bugs before obvious signs of infestation are visible. RioGin is researching a technology to reduce side effects and improve the efficacy of peptide drugs.

SRI SV is located on 25 acres in the Innovation Village at Rockingham, a 325-acre development less than two hours from Washington, D.C., and other mid-Atlantic cities.

About SRI Biosciences
SRI Biosciences carries out basic research, drug discovery, and drug development. SRI has all of the resources necessary to take R&D from initial discoveries to clinical trials. SRI's product pipeline has yielded marketed drugs, therapeutics currently in human testing, and additional programs at earlier stages. SRI Biosciences offers a wide range of contract research organization (CRO) services, helping government and industry clients and partners advance drugs and other biomedical products toward commercialization. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.
Visit SRI's website and Timeline of Innovation to learn more about SRI.


'/>"/>
SOURCE SRI International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
2. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Dyadic International Extends All Debt Maturity Dates
4. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
5. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
6. CIVCO Names Darrell Newcombe as Vice President of International Sales for Radiation Oncology
7. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. WIKA Process Solutions, Deer Park, Texas Acquires Gayesco International.
11. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Md. , Feb. 23, 2017 ... marketing of the PhenoTest BC Kit, performed on ... to identify organisms that cause bloodstream infections and ... likely to respond to (antibiotic sensitivity). The test ... to provide this important information, which can guide ...
(Date:2/24/2017)... MELBOURNE , Australien, 24. Februar 2017 /PRNewswire/ ... innovatives, diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für ... Vergleich mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen ... BioMedical und Aktualisierung zum Wachstum" finden Sie ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... ... 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist ... Throughout the month of February, patients who visit Hamlin Dental Group will receive a ... for two at the Cheesecake Factory. , Tickets are available for routine dental ...
(Date:2/23/2017)... ... 2017 , ... EBSCO Information Services (EBSCO) has ... Health and Care Excellence (NICE) framework. The agreement allows purchasers from libraries, ... search, order and purchase medical and healthcare-related content through GOBI ®, the ...
Breaking Medicine News(10 mins):